MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Holdings in BioNTech SE (NASDAQ:BNTX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its stake in BioNTech SE (NASDAQ:BNTX) by 16.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,415 shares of the company’s stock after selling 5,837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in BioNTech were worth $3,466,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Jones Financial Companies Lllp grew its position in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. grew its position in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE purchased a new position in BioNTech during the 4th quarter worth $90,000. Generali Investments CEE investicni spolecnost a.s. purchased a new position in BioNTech during the 4th quarter worth $137,000. Finally, AlphaCentric Advisors LLC purchased a new position in BioNTech during the 4th quarter worth $168,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Up 5.4%

Shares of NASDAQ BNTX opened at $97.80 on Tuesday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a 50-day moving average price of $97.36 and a 200 day moving average price of $108.72. The stock has a market capitalization of $23.51 billion, a price-to-earnings ratio of -46.57 and a beta of 1.35.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the business earned $1.90 earnings per share. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. Equities research analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on BNTX. BMO Capital Markets raised their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and issued a $134.00 target price (down previously from $145.00) on shares of BioNTech in a report on Wednesday, May 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Citigroup reaffirmed a “buy” rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Finally, Morgan Stanley lowered their target price on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average price target of $142.08.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.